Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HK1 | P19367 | 4/20 | 0.55 |
| ▸ | HK2 | P52789 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22282177 | 0.81 | LMNA (0.53) | HK1HK2MAPK1KDM4ELMNA | |
| SCHEMBL22861341 | 0.81 | LMNA (0.53) | HK1HK2MAPK1KDM4ELMNA | |
| SCHEMBL28953497 | 0.79 | HK1 (0.60) | HK1HK2MAPK1KDM4ELMNA | |
| SCHEMBL15514410 | 0.79 | HK1 (0.47) | HK1HK2MAPK1KDM4ELMNA | |
| SCHEMBL15508120 | 0.79 | HK1 (0.47) | HK1HK2MAPK1KDM4ELMNA | |
| SCHEMBL14780667 | 0.77 | HK1 (0.58) | HK1HK2KDM4ELMNACYP2D6 | |
| SCHEMBL10521162 | 0.77 | HK1 (0.58) | HK1HK2KDM4ELMNACYP2D6 | |
| SCHEMBL18803484 | 0.77 | HK1 (0.58) | HK1HK2KDM4ELMNACYP2D6 | |
| SCHEMBL15763312 | 0.77 | HK1 (0.58) | HK1HK2KDM4ELMNACYP2D6 | |
| SCHEMBL10522400 | 0.77 | HK1 (0.58) | HK1HK2KDM4ELMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-8067436-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | HK1 767/4885HK2 939/4885MAPK1 521/4885 |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | EGFR, EPHA2, ERBB4 | HK1 1088/4885HK2 1335/4885MAPK1 185/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | HK1 485/4885HK2 623/4885MAPK1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.